The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients (MedMemos)
MedMemos: An Intervention to Promote Medication Adherence in Pediatric Allogenic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant. The main study questions are:
- Is the MedMemos intervention acceptable to patients and families?
- Is the MedMemos intervention feasible for patients, families, and healthcare providers?
- Does MedMemos help patients and families take their medications better?
Participants will be asked to complete surveys, attend 4 intervention sessions, and use an electronic box or pill bottle to store their medications in.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Ahna LH Pai, PhD
- Número de teléfono: (614) 938-1601
- Correo electrónico: Ahna.Pai@nationwidechildrens.org
Copia de seguridad de contactos de estudio
- Nombre: Sarah N Drake, MS
- Número de teléfono: (614) 259-7462
- Correo electrónico: sarah.drake2@nationwidechildrens.org
Ubicaciones de estudio
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Reclutamiento
- Nationwide Children's Hospital
-
Contacto:
- Ahna LH Pai, PhD
- Número de teléfono: (614) 938-1601
- Correo electrónico: Ahna.Pai@nationwidechildrens.org
-
Contacto:
- Sarah N Drake, MS
- Número de teléfono: (614) 259-7462
- Correo electrónico: sarah.drake2@nationwidechildrens.org
-
Investigador principal:
- Ahna LH Pai, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Child had a Pediatric Allogeneic Hematopoietic Cell Transplant (PAHCT)
- Child is 0-12 years of age
- At the time of recruitment child is still in the hospital for PAHCT
- Child's primary caregiver is responsible for administering medical care and is willing to give consent to participate
- Child is prescribed an oral medication regimen at discharge
Exclusion Criteria:
- Caregiver does not speak English, Spanish, or Arabic
- Caregiver is not available to provide written permission for the child's participation
- EMR or medical team report of the caregiver's cognitive status precludes completion of questionnaires
- The child's medical status or condition precludes completion of the study questionnaires as determined by the physician or caregiver
- Caregiver is unwilling to store medication in an electronic monitor
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: MedMemos
This arm will provide participants with the MedMemos Intervention
|
MedMemos is a 4-session tailored adherence promotion intervention that will provide caregivers with a combination of tailored and standardized medication and adherence education videos and a "Medication Management Kit" that provides tailored strategies to target identified barriers to successful medication management.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Intervention Acceptability
Periodo de tiempo: At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
|
Intervention acceptability will be demonstrated by caregivers rating MedMemos a mean of ≥ 4 as measured on Acceptability of Intervention Measure, Feasibility of Intervention Measure, and Intervention Appropriateness Measure.
Each measure asks participants to rate statements on a scale of "Completely Disagree" to "Completely Agree" Higher scores indicate greater acceptability, feasibility, and appropriateness.
|
At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
|
|
Intervention Feasibility - Percentage of patients who enroll out of those approached
Periodo de tiempo: Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
|
Feasibility will be assessed by calculating enrollment rate (total number of patients enrolled / total number of patients approached).
Feasible enrollment will be achieved by enrolling 80% or more of eligible caregivers.
|
Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
|
|
Intervention Feasibility - Percentage of intervention sessions and follow-ups completed by enrolled participants.
Periodo de tiempo: Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
|
Feasibility will be assessed by calculating the percentage of MedMemos sessions attended and the number of follow-up visits completed.
Feasibility will be achieved if 80% or more of MedMemos sessions are attended by participants and if 80% or more of follow-up visits are completed by participants.
|
Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
|
|
Intervention Feasibility - Percentage of the intervention protocol delivered by the interventionist.
Periodo de tiempo: Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
|
Feasibility of the intervention delivery will be assessed by calculating the intervention fidelity.
Fidelity will be assessed by a member of the lab not involved in intervention delivery using a fidelity checklist developed by the study Principal Investigator.
Feasibility of the intervention delivery will be achieved if fidelity checklist scores are 80% are greater (80% or more of the intervention delivered across the study)
|
Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adherence to immunosuppressant medication as assessed by electronic monitor
Periodo de tiempo: Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
|
To establish proof-of-concept adherence to immunosuppressants will be monitored for all patients.
Proof-of-concept will be established if ≥75% children take ≥75% of their immunosuppressant medication doses at all follow-up time points as measured by electronic monitor.
|
Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Adherencia
- Niño
- Infección
- Cáncer
- Pediátrico
- Cuidador
- Padre
- EICH
- Adherencia a la medicación
- Transplante de médula osea
- Inmunosupresor
- Trasplante de células hematopoyéticas
- Insuficiencia de la médula ósea
- No Adherencia
- Adherence Promotion Intervention
- Transition to Outpatient
- Managing Medication Regimens
Términos MeSH relevantes adicionales
- Enfermedades hematológicas
- Enfermedades de la médula ósea
- Comportamiento
- Enfermedades hemic y linfáticas
- Adherencia y Cumplimiento del Tratamiento
- Comportamiento de salud
- Cumplimiento del paciente
- Aceptación del paciente de la atención médica
- Trastornos de insuficiencia de la médula ósea
- Neoplasias
- Infecciones
- Adherencia a la medicación
Otros números de identificación del estudio
Otros números de identificación del estudio
- STUDY00004461
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .